(Nasdaq: AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the ...

Amneal Pharmaceuticals (AMRX) announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment of moderately active ulcerative colitis in adults.

Recent clinical guidelines recommend mesalamine enemas and suppositories over oral mesalamine for people with proctosigmoiditis. Because proctosigmoiditis only affects the lower part of the colon ...

The initial impression from the colonoscopy and biopsy results was that the patient probably had ulcerative colitis and she was treated with mesalamine (4 g daily for 4 months), without improvement.

Ulcerative colitis (UC) can affect anyone — even those in the spotlight. These 9 celebrities share their struggles and successes living with UC.

1 Division of Molecular and Genetic Medicine, Royal Hallamshire Hospital, Sheffield, UK 2 Gastroenterology and Liver Unit, Royal Hallamshire Hospital, Sheffield, UK 3 Gastroenterology Unit, John ...

After hours: March 17 at 7:37:31 p.m. EDT Loading Chart for AMRX ...

BRIDGEWATER, N.J., January 29, 2025--Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025 BRIDGEWATER, N.J., January 23, 2025--Amneal ...

They found that patients using curcumin along with mesalamine (a medication for UC) were, on average, three times more likely to experience an improvement in symptoms than those who took ...

Crohn’s disease causes inflammation that spreads deeply into the layers of bowel tissue and can lead to life threatening complications. Crohn’s disease is a lifelong chronic condition that ...